Výsledky vyhledávání

Characteristics of Hydrochars Prepared from Cassava Residues Using Different Aqueous Media

Autor: Romeli Barbosa, Beatriz Escobar, Patricia Quintana, J. M. Baas, Cinthia J. Mena-Durán

Publikováno v: Waste and Biomass Valorization. 11:2857-2862

This study presents the synthesis and physicochemical characterization of functionalized carbon-based materials prepared from cassava residues (Manihot esculenta). Cassava residues were obtained from a local market, washed, dried and ground to small

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ae7c27b53df63f5a844d4bb132abd2c3
https://doi.org/10.1007/s12649-018-00561-1

Zobrazit plný text záznamu

Pharmacokinetics and safety of panitumumab in a patient with chronic kidney disease

Autor: Henk-Jan Guchelaar, Hans Gelderblom, J. M. Baas, L. L. Krens

Publikováno v: Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 81(1), 179-182

Purpose Data on panitumumab dosing in cancer patients with renal insufficiency are lacking. Here, we report a 63-year-old metastatic colorectal cancer patient with chronic kidney injury with a glomerular filtration rate of approximately 11 mL/min. Me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd5de577da55ceff46653c25b7b8c0d4
https://hdl.handle.net/1887/74786

Zobrazit plný text záznamu

Genome wide association study to identify predictors for severe skin toxicity in colorectal cancer patients treated with cetuximab

Autor: J. M. Baas, Linda Mol, Stefan Böhringer, L. L. Krens, Henk-Jan Guchelaar, Cornelis J. A. Punt, Hans Gelderblom

Publikováno v: PLoS ONE, 13(12):e0208080. Public Library of Science
PLoS ONE, Vol 13, Iss 12, p e0208080 (2018)
PLoS ONE

EGFR-antibodies are associated with significant skin toxicity, including acneiform rash and folliculitis. It remains impossible to predict the occurrence of severe skin toxicity due to the lack of predictive markers. Here, we present the first genome

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130c44c3296b240ac4e2cbbda1680134
https://pure.amc.nl/en/publications/genome-wide-association-study-to-identify-predictors-for-severe-skin-toxicity-in-colorectal-cancer-patients-treated-with-cetuximab(7af4981a-0a83-4935-b4b3-801fe3c67668).html

Zobrazit plný text záznamu

A fatal case of metastatic squamous cell carcinoma in a patient with myositis ossificans traumatica

Autor: I N, Vlasveld, H, Scheper, J, Stalenhoef, J M, Baas, J, van Dissel

Publikováno v: The Netherlands journal of medicine. 75(6)

Myositis ossificans traumatica is a rare disease associated with chronic wounds and fistulae. Chronic ulcers, fistulae and wounds can transform into squamous cell carcinoma, the so-called Marjolin's ulcer. We describe a rapid, progressive and fulmina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::a445a85f5b9227adc2f86fe03c0ab736
https://pubmed.ncbi.nlm.nih.gov/28741585

Zobrazit plný text záznamu

Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report

Autor: Henk-Jan Guchelaar, L. L. Krens, J. M. Baas, F.A. de Jong, Hans Gelderblom

Publikováno v: Cancer Chemotherapy and Pharmacology, 73(2), 429-433

Panitumumab is used for the treatment for metastatic RAS wild-type colorectal cancer (mCRC). It is likely that many of these patients will present with liver metastases and some with liver dysfunction. The pharmacokinetics in patients with hepatic im

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a26fc8921cdd9ed103ef2b34948af30
https://doi.org/10.1007/s00280-013-2353-0

Zobrazit plný text záznamu

Safety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patients

Autor: Henk-Jan Guchelaar, Hans Morreau, L. L. Krens, A. J. ten Tije, J. M. Baas, Frans L. G. Erdkamp, T. van Wezel, Hans Gelderblom

Publikováno v: Investigational New Drugs

SummaryIntroduction Cetuximab is registered for use in colorectal cancer (CRC) patients with RAS wild-type tumours only. Simvastatin blocks the mevalonate pathway and thereby interferes with the post-translational modification (prenylation) of KRAS.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a55659fcc523ad0eb60bff5438360b11
https://hdl.handle.net/1887/107175

Zobrazit plný text záznamu

Safety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patients

Autor: Monique M.E.M. Bos, Hans Morreau, Henk-Jan Guchelaar, J. M. Baas, Johanneke E.A. Portielje, Erdogan Batman, L. L. Krens, van Wezel T, Hans Gelderblom

Publikováno v: Anti-Cancer Drugs, 26(8), 872-877

Panitumumab has proven efficacy in patients with metastatic or locally advanced colorectal cancer patients, provided that they have no activating KRAS mutation in their tumour. Simvastatin blocks the mevalonate pathway and thereby interferes with the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c07f49c7e1a3d63ff1f488b234e9cb09
https://pubmed.ncbi.nlm.nih.gov/26053280

Zobrazit plný text záznamu

Pharmacokinetics and safety of cetuximab in a patient with renal dysfunction

Autor: Henk-Jan Guchelaar, J. M. Baas, Gilles Paintaud, L. L. Krens, Hans Gelderblom, Céline Desvignes, Michiel C. Verboom

Publikováno v: Cancer Chemotherapy and Pharmacology, 73(6), 1303-1306
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, Springer Verlag, 2014, epub ahead of print. ⟨10.1007/s00280-014-2462-4⟩

International audience; INTRODUCTION: In the literature, data on the effect of renal impairment on the pharmacokinetics of anticancer drugs are scarce. Here, we report a 68-year-old metastatic osteosarcoma patient with impaired renal function due to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01557de2dcab0a0fe8bb2db53baa174e
http://hdl.handle.net/1887/107332

Zobrazit plný text záznamu

Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study

Autor: Henk-Jan Guchelaar, Els R. Koomen, Cornelis J. A. Punt, J. M. Baas, Hans Gelderblom, L. L. Krens, Lieke H.J. Simkens

Publikováno v: PLoS ONE, 9(11). Public Library of Science
PLoS ONE, Vol 9, Iss 11, p e112201 (2014)
PLoS ONE
PLoS ONE, 9(11)

Statins may inhibit the expression of the mutant KRAS phenotype by preventing the prenylation and thus the activation of the KRAS protein. This study was aimed at retrospectively evaluating the effect of statin use on outcome in KRAS mutant metastati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d106c50241a1fc51f7f78349081bc36d
https://pure.amc.nl/en/publications/statin-use-is-not-associated-with-improved-progression-free-survival-in-cetuximab-treated-kras-mutant-metastatic-colorectal-cancer-patients-results-from-the-cairo2-study(24e30aaf-f4ac-43b5-96f3-906df773970f).html

Zobrazit plný text záznamu

Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction

Autor: J. M. Baas, L. L. Krens, Hans Gelderblom, Floris A. de Jong, Henk-Jan Guchelaar

Publikováno v: Journal of Clinical Oncology, 31(4)

594 Background: Panitumumab is used for the treatment of metastatic KRAS wild type (WT) colorectal cancer (mCRC). It is likely that many of these patients will present with liver metastases and some with liver dysfunction. The pharmacokinetics in pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0997d5d1633d3f4981762e2c9a107bc0
https://hdl.handle.net/1887/107673

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání